Jean Champagne

TL;DR: The STOP AF trial demonstrated that cryoballoon ablation is a safe and effective alternative to antiarrhythmic medication for the treatment of patients with symptomatic paroxysmal AF, for whom at least one antiarrHythmic drug has failed, with risks within accepted standards for ablation therapy.

TL;DR: Systematic clinical testing results in unmasking of the cause of apparently unexplained cardiac arrest in >50% of patients, and this approach assists in directing genetic testing to diagnose genetically mediated arrhythmia syndromes, which results in successful family screening.

TL;DR: PET/CT is useful in differentiating between CIED infection and recent post-implant changes and may guide appropriate therapy.

TL;DR: In patients with nonvalvular atrial fibrillation at high risk of cardioembolic events and absolute contraindications to anticoagulation, LAAC using the ACP device followed by dual-/single-antiplatelet therapy was associated with a low rate of embolic and bleeding events after a mean follow-up of 20 months.

TL;DR: The DISCERN AF study as mentioned in this paper monitored atrial fibrillation (AF) using an implantable cardiac monitor (ICM) to assess the incidence and predictors of asymptomatic AF before and after catheter ablation.